Influence of Pinealectomy and Long-term Melatonin Administration on Inflammation and Oxidative Stress in Experimental Gouty Arthritis

Arwa Fadil Haqi Ballur¹, Eyup Altinoz¹, Gurkan Yigitturk², Melike Ozgul Onal², Hulya Elbe², Yasemin Bicer¹, Melike Karayakali¹ and Mehmet Demir³,⁴

Received 11 December 2021; accepted 4 January 2022

Abstract—Gout is an inflammatory arthritis characterized by the deposition of monosodium urate (MSU) crystals in the joints or soft tissue. MSU crystals are potent inflammation inducers. Melatonin (MLT) is a powerful exogenous anti-inflammatory agent and effective in reducing cellular damage. In the present study, possible underlying mechanisms associated with anti-inflammatory and antioxidative effects were investigated in rats with gouty arthritis and melatonin deprivation treated with MLT. Fifty-six rats were divided into seven groups: control, sham control, pinealectomy (PNX), MSU (on the 30th day, single-dose 20 mg/ml, intraperitoneal), MSU + MLT (10 mg/kg/day for 30 days, intraperitoneal), MSU + PNX and MSU + PNX + MLT. PNX procedure was performed on the first day of the study. As compared to the controls, the results showed that MSU administration caused significant increases in oxidative stress parameters (malondialdehyde and total oxidant status). Besides, significant decreases in antioxidant defense systems (glutathione, superoxide dismutase and total antioxidant status) were observed. A statistically significant increase was found in the mean histopathological damage score in the groups that received MSU injection. It was found that histopathological changes were significantly reduced in the MSU + MLT group given MLT. In our study, it was determined that many histopathological changes, as well as swelling and temperature increase in the joint, which are markers of inflammation, were significantly reduced with MLT supplementation. These results suggest that melatonin ameliorates MSU-induced gout in the rat through inhibition of oxidative stress and proinflammatory cytokine production.

KEY WORDS: Gout; Monosodium urate crystals; Melatonin; Oxidative stress; Pinealectomy; Rat.

INTRODUCTION

Gout is a metabolic disease characterized by high serum urate level (hyperuricemia) triggered by purine catabolic pathway disorders [1], leading to the accumulation of monosodium urate (MSU) crystals in synovial...
joints and tissues [2]. The incidence and prevalence of gout are rising globally in recent years, imposing great disease burden worldwide [3]. Gout could be classified as primary and secondary gout. Primary gout is the most common type observed without any underlying disease that could lead to hyperuricemia. Secondary gout is a less common form exacerbated by the effects of genetic enzymatic defects, obesity, chemotherapy, alcohol poisoning and immunosuppressants [4]. Hyperuricemia could result due to hepatic overproduction of uric acid and/or inadequate excretion of urate in the small intestine and kidneys [5]. Hyperuricemia and gout prevalence has been increasing worldwide due to lifestyle changes, obesity, consumption of purine-rich nutrients, beverages with fructose, and spirits [6]. Increase in serum urate concentrations (hyperuricemia, ≥ 7.0 mg/dL) is manifested in the inflammation induced by the deposition of MSU crystals in cartilage, synovial bursa, tendons, or soft tissues [7]. It is currently accepted that the accumulation of crystalized MSU in the joints is a central risk factor for gout [8]. MSU crystals are potent inflammation inducers. These crystals stimulate a local inflammatory reaction within the joint, neutrophil recruitment, and the production of pro-inflammatory cytokines as well as other inflammatory mediators [9].

Melatonin (MLT) is an indolamine derived from the essential amino acid tryptophan via serotonin [10]. The main production site is the pineal gland located in the brain [11]. Circadian rhythms play a key role in the development of physiological and pathological responses based on daily environmental variations [12]. MLT is released to regulate the circadian rhythm and has anti-inflammatory [13], antitumor, and antiapoptotic effects [14]. Furthermore, MLT is a powerful antioxidant that reduces oxidative stress due to its capacity to directly scavenge reactive species and modulate the antioxidant defense system by increasing antioxidant enzyme activities [15].

Recent studies demonstrated that several factors, including MLT, play a role in the regulation of the rhythmic migration of neutrophils. However, the mechanisms underlying the regulation of the rhythmic neutrophil migration by endogenous MLT remain unclear [16]. In the pineal gland, where MLT is produced, changes associated with age such as decreased pinealocyte count, increased calcification, and decreased MLT production were observed [17]. The antioxidant catalase (CAT) and superoxide dismutase (SOD) enzymes and the endogenous antioxidant reduced glutathione (GSH) significantly protect the organism against the oxidative stress. GSH is found in almost all cells. It is among the main cellular antioxidants with various physiological functions [18].

In the present study, an experimental MSU crystal-induced rat model was set up to investigate the potential effects of MLT on gouty arthritis and gouty arthritis induced by melatonin deprivation. In the study, possible underlying mechanisms associated with anti-inflammatory and antioxidative effects were also investigated in rats with gouty arthritis and melatonin deprivation treated with MLT.

**MATERIAL AND METHODS**

The study was conducted on 56 male Wistar Albino rats that weighed 250–300 g. Rats were divided into 7 groups (n = 8). During the experiments, animals were kept in an environment under 21 ± 1 °C temperature and 12 h of light and 12 h of dark, and ad libitum standard rat chow and regular tap water were provided.

The study was approved by Zonguldak Bülent Ecevit University Faculty of Medicine Experimental Animals Ethics Committee (Protocol No: 2020–10-07/05). All experimental procedures were conducted in accordance with the Animal Ethics Committee Guidelines for experimental animals.

**Preparation and Injection of Melatonin Solution**

MLT was dissolved in 0.5% ethanol (0.5%) and adjusted to the adequate concentration with physiological saline solution. The final concentration of ethanol in the solution was set to 0.5% [19]. Based on the study group, 10 mg/kg/day i.p. MLT or MLT solution was administered for 30 days.

**Preparation and Injection of MSU Crystals**

MSU crystals (20 mg/ml) were prepared as 50 µL sterile phosphate buffer solution (PBS). Rats were anesthetized with 80 mg/kg i.p. ketamine (Ketalar-Eczacıbaşı/Turkey) and 8 mg/kg xylazine (Rompun-Bayer/Turkey) [20]. After the anesthesia, 50 µL PBS MSU was injected into the medial side of the left tibiotarsus joint.
The Pinealectomy Procedure

An incision was applied on the scalp, equidistant from the two eyes of the anesthetized rats, between the back of the nose and the nape. The periosteum was stripped to reveal the lambda. A circular incision was applied in the upper part of the skull with a micromilling drill (Proxxon MICROMOT 50/E, Germany) to accommodate the access of forceps tip. The pineal gland located under the venous sinus was removed massively with the forceps. Then, the removed bone piece was replaced, the scalp was sutured, and 10% povidone iodine was applied.

Study Design

Rats were separated into 7 groups of 8 animals each as follows:

Control group: No application was conducted in this group.
Sham Pinealectomy (PINX) group: The rats in this group underwent sham PINX on the first day of the experiment. Intraperitoneal (i.p.) 0.9% saline (MLT solvent) injection was administered for 30 days after the first day, and a single intra-articular (i.a.) 50 µl phosphate buffer solution (PBS; MSU solvent) injection was administered on the 30th day of the study.
MSU group: MLT solvent was administered intraperitoneally to the rats in this group for 30 days. On the 30th day, single-dose 20 mg/ml MSU was administered in 50 µL of sterile PBS [21].
MSU + MLT group: The rats in this group were administered 10 mg/kg/day MLT i.p. for 30 days [22]. On the 30th day, single-dose 50 µl MSU was injected i.a.
PINX group: The rats in this group underwent PINX procedure on the first day of the study.
PINX + MSU group: The rats in this group underwent PINX on the first day of the study. MLT solution was administered intraperitoneally for 30 days. On the 30th day, single-dose 50 µl MSU was injected i.a.
PINX + MSU + MLT group: The rats in this group underwent PINX procedure on the first day of the study. MLT solution was administered intraperitoneally for 30 days. On the 30th day, single-dose 50 µl MSU was injected i.a.

On the 30th day of the study, the circumference of the ankle joint was measured with a digital caliper in all groups. Edema in the ankle was determined based on the increase in ankle circumference [23]. Twenty-four hours after the induction of gout (determined based on the ankle circumference measurements), rats were decapitated, and blood and joint tissue samples were collected. Malondialdehyde (MDA) level, an end product of lipid peroxidation, and GSH level, an endogenous non-enzymatic antioxidant, and SOD and CAT antioxidant enzyme activities were determined in blood serum. Furthermore, histopathological evaluation of the joint tissues was conducted.

The Analysis of Ankle Circumference and Joint Skin Temperature Changes

After all applications were conducted (on day 30), the circumference of the left tibiotarsal joint of each rat was measured with a digital caliper after 0, 2, 8, 16, and 24 h. Similarly, the joint temperatures of these rats were measured with a precision thermometer.

Histopathological Evaluation

After the procedures, the rats were killed with ketamine/xylazine anesthesia. The heart tissue samples were fixed in 10% neutral formalin buffer. Tissues were washed in running water and demineralized in 10% ethylenediaminetetraacetic acid (EDTA) solution with a 7.4 pH for ~4 weeks at room temperature (mean temperature: 28 °C). In EDTA samples, the solution was replaced every 2 or 3 days. Then, the samples were transferred into xylene to achieve transparency and embedded in paraffin. Six 6-µm paraffin blocks were incised, mounted on slides, and stained with hematoxylin and eosin (H-E). The tissue sections were examined with light microscopy. The parameters evaluated for severity of articular damage included cartilage destruction, inflammation, and bone erosion in 10 microscopic fields in each section. Histopathological findings were analyzed with grading scales, as described above [24]. Cartilage destruction and bone erosion were graded based on a scale between 0 and 3, where 0 depicted no change, 1 depicted identifiable changes, 2 depicted moderate changes at few sites, and 3 depicted severe cartilage destruction and bone erosion. Inflammation was also graded on a 0–3 scale, where 0 reflected no cells with inflammation, 1, low increase in inflammatory cell count, 2, moderate increase in inflammatory cell count, and 3, severe increase in inflammatory cell
count. All sections were examined with a Nikon Eclipse 80i light microscope and Nikon Image Analysis system (Tokyo, Japan).

**Statistical Analysis**

Statistical analysis was conducted with the SPSS for Windows v. 14.0 (SPSS Inc., Chicago, III., USA) statistics software. All data are given in arithmetic mean ± SE. The normal distribution of continuous variable data was determined with the Shapiro–Wilk test. The variables did not exhibit normal distribution (p < 0.05). Kruskal–Wallis and Mann–Whitney U tests were employed to compare the variables in the groups. p < 0.05 was considered significant.

**Biochemical Analysis**

After the anesthesia, blood samples were collected from the abdominal vein via laparotomy and the animals were decapitated. The blood samples were stored at room temperature for about one hour for coagulation, and then the serum samples were obtained with centrifugation at 4000 rpm for 20 min. After the serum samples were separated into Eppendorf tubes, they were stored in a deep freezer at -80 °C for biochemical tests.

**Preparation of the Samples**

The MDA, GSH, SOD, CAT analyses were conducted on the samples, and total antioxidant (TAS), total oxidant (TOS) levels, oxidative stress index (OSI), interleukin-6 (IL-6), and protein levels were determined.

**Measurement of Serum MDA Level**

Serum MDA analysis was conducted based on the method described by Ohkawa et al. [25]. After the serums were mixed with 1% H$_3$PO$_4$ and 0.6% thiobarbituric acid in a plugged glass tube, they were incubated in a boiling water bath for 45 min after the tube plugs were tightly wrapped with aluminum foil. Then, the mixture was extracted with n-butanol, and the pink color separated in the n-butanol phase with centrifuge and placed in microplate wells based on the study groups and measured at 535 nm wavelength in an ELISA reader to determine the MDA level. N-butanol was employed as the blank, and tetramethoxpropane was used as the standard. The findings are presented in µmol/L.

**Measurement of Serum GSH Level**

Serum GSH analysis was conducted with the method described by Ellman [26]. After the serums were deproteinized, they were reacted with 5,5'-dithiobis 2-nitrobenzoic acid (DTNB) in an Eppendorf tube and incubated to form a yellow-green color. The colored product was placed on microplates based on the study group and measured at a wavelength of 410 nm in an ELISA reader to determine the GSH level. Different dilutions prepared with distilled water were used as blank, and 5 mM/L stock GSH solution was used as standard. Results are presented in µmol/L.

**Measurement of Serum SOD Enzyme Activity**

Serum SOD activities were determined with the method developed by Sun et al. [27]. Superoxide radicals are formed by the xanthine–xanthine oxidase reaction in the experimental medium. These radicals lead to a blue formazan by reducing NBT (nitroblue tetrazolium). Serum SOD activities were determined based on the measurement of this blue-colored formazan at 560 nm in an ELISA reader. The results are presented in U/g protein.

**Measurement of Serum CAT Enzyme Activity**

Serum CAT activities were determined with the method proposed by Aebi et al. [28]. The supernatant and H$_2$O$_2$ phosphate buffer (pH: 7.5 mM) were mixed in the experiment medium. H$_2$O$_2$ is broken down to H$_2$O and O$_2$ due to serum CAT activity. Degradation of hydrogen peroxides in the medium leads to a decrease in absorbance at 240 nm. The decrease in absorbance was observed for 1 min to calculate the CAT activity. Results are presented in K/g protein.

**Measurement of Serum Protein Level**

To calculate the serum SOD and CAT enzyme activities, the protein levels were determined with the method published by Lowry et al. [29]. The resulting blue color was measured with an ELISA reader at 700 nm wavelength to calculate the protein content. Results are presented in mg/ml.
Measurement of Serum TOS Level

Serum TOS was measured with the Erel’s method [30]. Total oxidant status was determined based on the kit procedure (Rel Assay Diagnostics, Gaziantep Turkey). The colored compounds were measured with an ELISA reader at 530 nm wavelength to calculate the serum TOS. 20 µmol/L H₂O₂ solution was used as the standard. Results are presented in µmol H₂O₂ equiv./L.

Measurement of Serum TAS Level

Serum TAS was determined with the Erel’s method [30]. Total antioxidant status was determined with the kit procedure (Rel Assay Diagnostics, Gaziantep, Turkey). Reagent 1 was added to the supernatant placed on microplates as per the kit instructions, and first reading was conducted at 660 nm, and the second reading was conducted after the reagent 2 was added.

Fig. 1  Effects of MLT on joint swelling induced by MSU crystal in rats. MSU crystals led to a significant increase in ankle circumference of rats compared to normal control rats. Of note, treatment with MLT (10 mg/kg/day) significantly suppressed MSU crystal-induced ankle swelling. (Representative images of the left leg from each group are shown. Arrows indicate location of measurement).

Fig. 2  The mean ankle circumference of MSU-induced gout model. Data are expressed mean ± SE (n=8). p < 0.05 was regarded as significant. * p < 0.05 vs group 1 ** p < 0.05 vs group 2 *** p < 0.05 vs group 3 * p < 0.05 vs group 4 ** p < 0.05 vs group 5 *** p < 0.05 vs group 6.
The difference between the two absorbances was determined to calculate the serum TAS. Trolox, a water-soluble analog of vitamin E, was used as the calibrator. Results are presented in mmol Trolox equiv./L.

**Measurement of Serum OSI Level**

Serum OSI was calculated with the Erel’s method [30]. OSI equals TOS divided by TAS: OSI (Arbitrary Unit) = TOS (μmol H₂O₂equiv/1) / TAS (mmol Trolox equiv/l) × 10. The findings are reported in arbitrary units (AU).

**Measurement of Serum IL-6 Level**

Serum IL-6 levels were determined with the Rat ELISA kit (Cat. No E0135Ra) purchased from Bioassay Technology Laboratory (BT Lab, CHINA) based on the kit protocol, and the results are presented in pg/ml.

**RESULTS**

**The Effects of MLT on MSU Crystal-Induced Ankle Circumference and Skin Temperature in Rats**

Since the increases in temperature and swelling in joints and periarticular regions are the most common symptoms of gout, we first investigated whether melatonin could prevent these symptoms caused by MSU. The circumference of the knee joint was measured 0, 2, 8, 16, and 24 h after the intra-articular MSU injection. The comparison of MSU injection groups and the other groups revealed a significant increase in ankle circumference (Fig. 1).

In particular, significant increases in ankle circumference and skin temperature in the above-mentioned region were identified after 2 h in MSU group rats without MLT treatment (p < 0.001) (Figs. 2 and 3). However, the ankle circumference and joint skin temperature
of the rats with MLT treatment (MSU + MLT and MSU + PINX + MLT groups) before MSU injection did not increase due to MLT treatment (Figs. 2 and 3). MLT treatment prevented MSU crystal-induced inflammation.

Comparison of Serum MDA and GSH Between the Groups

PINX application to experimental animals (PINX group) led to significant increases in MDA levels when compared to control and SHAM groups (p < 0.001), while significant decreases (p < 0.001) were observed in GSH levels (Fig. 4). Furthermore, MSU injection (MSU group) led to an increase in MDA levels when compared to the control group (p < 0.001), while significant decreases were observed in GSH levels (p < 0.001). On the other hand, MLT treatment before the MSU injection (MSU + MLT group) led to significant decreases in MDA levels (p < 0.001), while significant increases were observed in GSH levels (p < 0.001) when compared to the group without MLT treatment (MSU group). Also, the comparison of the animals that underwent PINX before MSU injection (MSU + PINX) and the animals with MLT treatment before MSU injection (MSU + MLT) revealed that MDA level significantly increased and GSH level decreased (p < 0.001) in the group without MLT treatment. On the other hand, MLT treatment before MSU injection after the PINX procedure (MSU + PINX + MLT group) led to decreases in MDA levels (p < 0.001), while GSH levels significantly improved (p < 0.001) when compared to the group without MLT treatment (MSU + PINX) (Fig. 4).

Comparison of Serum SOD and CAT Activities Between the Groups

It was observed that PINX procedure (PINX group) led to a significant decrease in antioxidant CAT (p < 0.001) and SOD (p < 0.001) enzyme levels when compared to the control group (Fig. 4). Furthermore, MSU injection (MSU group) led to a decrease in CAT (p < 0.005) and SOD (p < 0.001) activities when compared to the control group. On the other hand, MLT treatment before MSU injection (MSU + MLT group) led to an insignificant increase in CAT activity, while a significant increase was observed in SOD activity.
activity (p < 0.001) when compared to the group without MLT treatment (MSU group). The comparison of the animals that underwent PINX before MSU injection (MSU + PINX) and the animals with MLT treatment before MSU injection (MSU + MLT) demonstrated that CAT activity decreased insignificantly in the MSU + PINX group without MLT treatment, while SOD activity significantly decreased (p < 0.001). On the other hand, MLT treatment before MSU injection after PINX procedure (MSU + PINX + MLT group) led to no significant improvement in CAT activity when compared to the group without MLT treatment (MSU + PINX), while significant improvements were observed in SOD activities (p < 0.001) (Fig. 4).

Comparison of Serum TAS, TOS, and OSI Between the Groups

PINX procedure (PINX group) led to a significant decrease in serum TAS and significant increases in TOS and OSI index when compared to the control group (p < 0.001) (Fig. 5). Furthermore, MSU injection (MSU group) led to significant decreases in serum TAS and significant increases in TOS and OSI index when compared to the control group (p < 0.001). MLT treatment before MSU injection (MSU + MLT group) led to a significant improvement in TAS (p < 0.001), an insignificant decrease in TOS, and a significant decrease in OSI index when compared to the group without MLT treatment (MSU group) (p < 0.001). The comparison of the animals that underwent PINX before MSU injection (MSU + PINX) and the animals with MLT treatment before MSU injection (MSU + MLT) revealed a significant decrease in TAS in the MSU + PINX group without MLT treatment (p < 0.005) and significant increases in TOS and OSI index (p < 0.001). On the other hand, significant increases were observed in TAS (p < 0.005) and significant improvements were observed in TOS and OSI index (p < 0.001) in the group where MLT was administered after the PINX procedure and before MSU injection (MSU + PINX + MLT group) when compared to the group without MLT treatment (MSU + PINX group) (Fig. 5).

![Graphs showing comparisons of TAS, TOS, and OSI between different groups.](image-url)
Comparison of Group Serum IL-6 Levels

PINX procedure (PINX group) led to significant increases in serum IL-6 level when compared to the control (p < 0.001), while MSU injection (MSU group) led to increases in IL-6 levels when compared to both the control (p < 0.001) and PINX groups (p < 0.001) (Fig. 6). On the other hand, MLT treatment before MSU injection "Fig. 6" The mean IL-6 levels of MSU-induced gout model. Data are expressed mean ± SE (n = 8). p < 0.05 was regarded as significant. * p < 0.05 vs group 1 and 2 ** p < 0.05 vs group 3 *** p < 0.05 vs group 4 # p < 0.05 vs group 5 ## p < 0.05 vs group 6.

**Comparison of Group Serum IL-6 Levels**

PINX procedure (PINX group) led to significant increases in serum IL-6 level when compared to the control (p < 0.001), while MSU injection (MSU group) led to increases in IL-6 levels when compared to both the control (p < 0.001) and PINX groups (p < 0.001) (Fig. 6). On the other hand, MLT treatment before MSU injection "Fig. 6" The mean IL-6 levels of MSU-induced gout model. Data are expressed mean ± SE (n = 8). p < 0.05 was regarded as significant. * p < 0.05 vs group 1 and 2 ** p < 0.05 vs group 3 *** p < 0.05 vs group 4 # p < 0.05 vs group 5 ## p < 0.05 vs group 6.

**Comparison of Group Serum IL-6 Levels**

PINX procedure (PINX group) led to significant increases in serum IL-6 level when compared to the control (p < 0.001), while MSU injection (MSU group) led to increases in IL-6 levels when compared to both the control (p < 0.001) and PINX groups (p < 0.001) (Fig. 6). On the other hand, MLT treatment before MSU injection "Fig. 6" The mean IL-6 levels of MSU-induced gout model. Data are expressed mean ± SE (n = 8). p < 0.05 was regarded as significant. * p < 0.05 vs group 1 and 2 ** p < 0.05 vs group 3 *** p < 0.05 vs group 4 # p < 0.05 vs group 5 ## p < 0.05 vs group 6.

**Comparison of Group Serum IL-6 Levels**

PINX procedure (PINX group) led to significant increases in serum IL-6 level when compared to the control (p < 0.001), while MSU injection (MSU group) led to increases in IL-6 levels when compared to both the control (p < 0.001) and PINX groups (p < 0.001) (Fig. 6). On the other hand, MLT treatment before MSU injection "Fig. 6" The mean IL-6 levels of MSU-induced gout model. Data are expressed mean ± SE (n = 8). p < 0.05 was regarded as significant. * p < 0.05 vs group 1 and 2 ** p < 0.05 vs group 3 *** p < 0.05 vs group 4 # p < 0.05 vs group 5 ## p < 0.05 vs group 6.
(MSU + MLT group) led to a significant decrease in IL-6 level when compared to the group without MLT treatment (MSU group) (p < 0.001). Furthermore, the comparison of the animals that underwent PINX before MSU injection (MSU + PINX) and the animals with MLT treatment before MSU injection (MSU + MLT) revealed a significant increase in IL-6 levels in the MSU + PINX group when compared to the group without MLT treatment (p < 0.001). The comparison of the animals that underwent PINX before MSU injection (MSU + PINX) and the animals with MLT treatment before MSU injection (MSU + MLT) revealed a significant increase in IL-6 levels in the MSU + PINX group without MLT treatment (p < 0.001). On the other hand, MLT treatment before MSU injection after PINX procedure (MSU + PINX + MLT group) led to a significant decrease (p < 0.01) in IL-6 level when compared to the group without MLT treatment (MSU + PINX) (Fig. 6).

**Histopathological Findings**

Control and sham groups exhibited normal histological appearances (Fig. 7A, D), and there was no significant difference between these groups (p > 0.05). Mild inflammation was obvious in the PINX group (Fig. 7E, F). Histopathological findings such as cartilage tissue damage, bone erosion, severe inflammatory cell infiltration and hemorrhage in the surrounding tissues, synovial membrane thickening were significant in the MSU group (Fig. 8A, B, C). The comparison of the control, Sham, and PINX groups with the MSU group revealed a statistically significantly higher mean histopathological damage score in MSU group sections. Histopathological changes were significantly reduced with melatonin treatment in the MSU + MLT group (Fig. 9A, B, C). The most severe damages were observed in the MSU + PINX group (Fig. 8D, E, F). The comparison of the MSU + PINX + MLT and MSU groups revealed no statistically significant difference (p > 0.05) (Fig. 9D, E, F). The mean histopathological damage scores are presented in Fig. 10.

**DISCUSSION**

The present study aimed to determine whether the development of gout was affected by MLT deprivation (pinealectomy) and whether exogenous MLT administration had a protective effect against gout histologically and biochemically.
It was demonstrated that MLT is a specific antioxidant due to its amphiphilic property that allows penetration of physiological barriers, reducing oxidative damage in both lipid and aqueous cell environments [31]. The antioxidant MLT activity is the result of three complementary factors: (a) direct effect due to free...
Influence of Pinealectomy and Long-term Melatonin Administration on Inflammation and Oxidative…

Shenqi Decoction (ZSD) on MSU crystal-induced gouty arthritis was investigated, it was determined that swelling of the ankle was the most significant symptom within 24 h following the MSU injection. NALP inflammation by MSU injection leads to the conversion of pro-caspase-1 to active caspase-1, which indirectly results in active IL-1β production. In addition to the chemotactic factors, IL-1β could activate several proinflammatory cytokines such as TNF-α and nuclear factor kappa B (NF-κB), which are critical for the initiation and propagation of the inflammatory response and contribute to bone erosion and damage. Furthermore, ZSD treatment led to the downregulation of NACHT domain leucine-rich repeat protein (NALP)1 and NALP6 inflammasome expression levels. ZSD treatment prevented MSU crystal-induced inflammatory responses and reduced serum TNF-α and IL-1β levels and inhibited the activation of NF-κB [42].

In our study, the most prominent symptoms observed within the 24-h post-injection period included ankle swelling and high joint temperature in the model groups (MSU group and MSU + PINX group) with intra-articular MSU injection (20 mg/ml). The presence of these symptoms indicated that the desired model was successfully created. Furthermore, it was determined that ankle swelling and high joint temperature were significantly reduced in the MSU + MLT and MSU + PINX + MLT groups treated with melatonin when compared to the model groups, demonstrating that melatonin could inhibit the inflammation induced by MSU.

Intra-articular MSU injection is a good experimental model in rats that mimics the manifestation of gout in humans (intra-articular MSU deposition, joint redness, warmth, and pain) [39]. The deposition of MSU crystals in the joints induces oxidative stress in defensive cells and leads to the release of proinflammatory mediators [40].

In a previous study, it was determined that serum melatonin levels and the expression of mRNA melatonin receptor 2 were significantly lower in acute gout patients when compared to healthy individuals. In the present study, to confirm the in vivo role of melatonin, acute gout inflammation was induced by MSU administration to C57B/6L mice, and it was demonstrated that the mouse paw thickness increased significantly in the model group when compared to the control group. The study findings demonstrated that melatonin reduced both paw thickness and the inflammation index, as well as the IL-1β, IL-6 mRNA levels, and NLR family pyrin domain that included 3 (NLRP3) inflammasomes in the mouse model [41]. In another study where the impact of Zhisheng Shenqi Decoction (ZSD) on MSU crystal-induced gouty arthritis was investigated, it was reported that swelling of the ankle was the most significant symptom within 24 h following the MSU injection. NALP inflammation by MSU injection leads to the conversion of pro-caspase-1 to active caspase-1, which indirectly results in active IL-1β production. In addition to the chemotactic factors, IL-1β could activate several proinflammatory cytokines such as TNF-α and nuclear factor kappa B (NF-κB), which are critical for the initiation and propagation of the inflammatory response and contribute to bone erosion and damage. Furthermore, ZSD treatment led to the downregulation of NACHT domain leucine-rich repeat protein (NALP)1 and NALP6 inflammasome expression levels. ZSD treatment prevented MSU crystal-induced inflammatory responses and reduced serum TNF-α and IL-1β levels and inhibited the activation of NF-κB [42].

In our study, the most prominent symptoms observed within the 24-h post-injection period included ankle swelling and high joint temperature in the model groups (MSU group and MSU + PINX group) with intra-articular MSU injection (20 mg/ml). The presence of these symptoms indicated that the desired model was successfully created. Furthermore, it was determined that ankle swelling and high joint temperature were significantly reduced in the MSU + MLT and MSU + PINX + MLT groups treated with melatonin when compared to the model groups, demonstrating that melatonin could inhibit the inflammation induced by MSU.

The primary pathological characteristic of gout is the endothelial activation induced by IL-1β, TNF-α, and IL-6, the influx of neutrophils into the joint fluid, and the ensuing monocyte influx [43]. After the monocytes and neutrophils are activated, these cells actively phagocytose the MSU crystals, which then trigger inflammatory caspase responses. Thus, the inhibition of inflammatory cell infiltration could be an effective therapeutic strategy against gout inflammation[44]. In the present study, IL-6 levels were determined since IL-6 is a prominent cytokine in gout inflammation. Serum IL-6 levels were significantly higher in the MSU injection model groups (MSU and MSU + PINX groups). In a study where the impact of rebamipide on acute gouty arthritis was investigated in MSU-induced rats, it was reported that IL-1β, IL-6, IL-10, and TNF-α serum levels were high [45]. In another study where the effect of polygonum cuspidatum ethanol extract on acute gouty arthritis was investigated in mice on the NLRP3/ASC/caspase-1 axis, it was reported that ankle joint swelling significantly increased in model mice, while IL-1β, IL-6, and TNF-α...
expressions increased significantly [46]. In another study, it was revealed that IL-1β and IL-6 mRNA expression levels were inhibited by MLT [41]. In the current study, it was determined that IL-6 levels decreased in the MSU + MLT and MSU + PINX + MLT groups treated with MLT when compared to the model groups that were not treated with MLT. MLT has quite low toxicity and adverse effects, as well as desirable properties found in ideal antioxidants. Thus, melatonin is an attractive candidate to prevent oxidation-induced damages [47].

All living organisms are constantly exposed to both endogenous and exogenous oxidizing agents. Free radical production induced by oxidative stress plays a key role in the development of tissue damages and aging [48]. Phagocytosis of MSU crystals by tissue macrophages leads to the production of ROS, inflammatory cytokines, and chemokines [49]. The oxygen radicals are produced by the metabolic conversion of hypoxanthine and xanthine to uric acid, as well as neutrophil collection in the necrotic area in tissues. Subsequent reactions produce cytotoxic and oxidation products as well as lipid peroxides, including MDA [50]. In a study where the effects of Selaginella moellendorfii were investigated in MSU-induced gout model in rats, it was observed that plasma MDA levels increased, while the serum SOD levels decreased in the gout model group when compared to rats in the control group [51]. In another study that investigated plasma paraoxonase-1, oxidized low-density lipoprotein, and lipid peroxidation levels in gout patients, a decrease in SOD levels and an increase in MDA levels were observed in gout patients [52]. In the present study, pinealectomy (PINX group) and MSU injection (MSU group) led to significant increases in MDA levels when compared to control and sham groups. The increase in MDA levels was inducted by increased ROS and lipid peroxidation. It was also determined that lipid peroxidation and MDA levels decreased in groups treated with melatonin before injections and the procedure (MSU, PINX) due to the strong antioxidant property of the melatonin. Antioxidant enzymes such as SOD and CAT form the main line of defense against oxidative damage. The decrease in SOD and CAT activities reflects a significant increase in free radicals, superoxide, and hydrogen peroxide that lead to cellular damage [53]. In a study that investigated oxidative stress and the antioxidant effect of allopurinol in gout patients, it was reported that CAT and SOD levels were significantly lower before the treatment when compared to the control group, and these variables improved after allopurinol treatment [54]. In another study conducted with MSU-induced rats, significant decreases were observed in antioxidant enzymes such as SOD, CAT, and GSH. In our study, pinealectomy (PINX group) and MSU injection (MSU group) led to decreases in CAT and SOD antioxidant enzyme activities when compared to the control groups. Furthermore, MLT treatment before MSU injection led to a significant increase in SOD enzyme activity, while PINX before MSU injection led to a significant decrease in SOD enzyme activity. However, the increase in CAT levels after MLT treatment before MSU injection and the decrease in CAT levels after PINX procedure before MSU injection were not statistically significant. In a study on MSU-induced gouty arthritis in mice, it was observed that MSU significantly depleted GSH [55]. In another study on MSU-induced gouty arthritis, the effect of cyclopentadione-type 15-deoxy-D12,14-prostaglandin J2, a natural ligand that stimulates peroxisome proliferator-activated receptor gamma (PPAR-γ), on gout was investigated [56]. It was reported that oxidative stress elevated by MSU injection was reduced with 15d-PGJ2 and this effect was associated with its antioxidant properties [57]. On the other hand, 15d-PGJ2 increased the scavenger receptor CD36 expression in murine macrophages due to Nrf2 activation, and PPAR-γ activation increased endogenous antioxidant defenses by upregulating Nrf2/HO-1 signaling [58].

In our study, PINX procedure and MSU injection led to a significant decrease in GSH level, which could be due to the increase in oxidative stress, indicating that GSH was depleted to overcome oxidative stress via the reaction with and neutralizing superoxide radicals. While significant increases were observed in GSH and TAS in our rat groups treated with melatonin, significant improvements were observed in TOS and OSI. Several studies emphasized that persistent MSU crystal deposition and inflammation could lead to chronic gout, which results in bone erosion, joint destruction, and significant disabilities [59].

The histopathological damage scores determined in our study revealed that MSU increased the cartilage tissue damage, bone erosion in certain regions, widespread inflammatory cell infiltration in the surrounding tissue, while melatonin significantly reduced these histopathological changes.

The protective effect of endogenous MLT is manifested by the reduction in cellular damage induced by free radicals or via immunity regulation. However, in
cases where endogenous MLT is insufficient, the need for exogenous MLT administration could be necessary to sustain the possible protective effects. Thus, it could be suggested that melatonin could lead to improvements in the pathological changes observed in gout due to its antioxidant and anti-inflammatory properties; thus, it could be employed as a supplement to medical treatment. However, further clinical studies are required for more concrete evidence.

AUTHOR CONTRIBUTION

Mehmet Demir performed experiments and drafted the manuscript. Eyup Altinoz performed experiments and analyzed data, and Arwa Fadil Haqi Ballur, Yasemin Bicer, Melike Karayakali collected samples and analyzed data. Gurkan Yigitturk, Melike Ozgul Onal, Hulya Elbe helped in histopathological examination.

FUNDING

The research was supported by Karabuk University Scientific Research Fund (TSA-2020–2346).

DATA AVAILABILITY

The data used to support the findings of this study are available from the corresponding author on reasonable request.

Declarations

Ethical Approval and Consent to Participate The study was approved by the Experimental Animals Ethics Committee of Zonguldak Bulent Ecevit University, Faculty of Medicine (Protocol No: 2020–10-07/05).

Consent to Publish Not applicable.

Competing Interests The authors declare no competing interests.

REFERENCES

1. Han, Q., W. Bing, Y. Di, L. Hua, L. Shi-He, Z. Yu-Hua, H. Xiu-Guo, W. Yu-Gang, F. Qi-Ming, and Y. Shih-Mo. 2016. Kinseaside screening with a microfluidic chip attenuates gouty arthritis through inactivating NF-κB signaling in macrophages and protecting endothelial cells. Cell Death & Disease 7: e2350–e2350.

2. Choi, H.K., K. Atkinson, E.W. Karlson, W. Willett, and G. Curhan. 2004. Purine-rich foods, dairy and protein intake, and the risk of gout in men. New England Journal of Medicine 350: 1093–1103.

3. Weaver, A.L. 2008. Epidemiology of gout. Cleveland Clinic Journal of Medicine 75: S9–S12.

4. Schlesinger, N. 2005. Diagnosis of gout: Clinical, laboratory, and radiologic findings. The American Journal of Managed Care 11: S443–S450.

5. Ota-Kontani, A., H. Hirata, M. Ogura, Y. Tsuchiya, and M. Harada-Shiba. 2020. Comprehensive analysis of mechanism underlying hypouricemic effect of glucosyl hesperidin. Biochemical and Biophysical Research Communications 521: 861–867.

6. Mahor, D., and G.S. Prasad. 2018. Biochemical Characterization of Kluyveromyces lactis Adenine Deaminase and Guanine Deaminase and Their Potential Application in Lowering Purine Content in Beer. Frontiers in Bioengineering and Biotechnology 6: 180.

7. Puig, J.G., L. Beltrán, C.M. Chew, R. Torres, D.T. Márquez, and A.P. Reino. 2016. Ultrasound in the diagnosis of asymptomatic hyperuricemia and gout. Revista Clinica Española (English Edition) 216: 445–450.

8. Rasheed, H., C. McKinney, L.K. Stamp, N. Dalbeth, R.K. Topless, R. Day, D. Kannangara, K. Williams, M. Smith, and M. Jansson. 2016. The toll-like receptor 4 (TLR4) variant rs2149356 and risk of gout in European and Polynesian sample sets. PloS One 11: e0147939.

9. so, A. 2008. Development of the scientific and clinical understanding of gout. Arthritis Research & Therapy 10: 1–6.

10. Pereira, N., M.F. Naufel, E.B. Ribeiro, S. Tufik, and H. Hachul. 2020. Influence of dietary sources of melatonin on sleep quality: A review. Journal of food science 85: 5–13.

11. Stanciu, A.E., A. Zamfir-Chiru-Anton, M.M. Stanciu, A.P. Stoian, V. Jinga, C. Nitipir, A. Bucur, T.S. Pituru, A.L. Arsene, and C.M. Dragoi. 2020. Clinical significance of serum melatonin in predicting the severity of oral squamous cell carcinoma. Oncology Letters 19: 1537–1543.

12. Ertosun, M.G., G. Kocak, and O.N. Ozes. 2019. The regulation of circadian clock by tumor necrosis factor alpha. Cytokine & Growth Factor Reviews 46: 10–16.

13. Luo, J., Z. Zhang, H. Sun, J. Song, X. Chen, J. Huang, X. Lin, and R. Zhou. 2020. Effect of melatonin on T/B cell activation and immune regulation in pinealectomy mice. Life Sciences 242: 117191.

14. Liu, X.-W., Y. Zi, Y.-E. Liu, Y.-B. Zhang, L.-B. Xiang, and M.-x Hou. 2015. Melatonin exerts protective effect on N2a cells under hypoxia conditions through Zip1/ERK pathway. Neuroscience Letters 595: 74–80.

15. Yang, H.L., W.J. Zhou, C.J. Gu, Y.H. Meng, J. Shao, D.J. Li, and M.Q. Li. 2018. Pleiotropic roles of melatonin in endometriosis, recurrent spontaneous abortion, and polycystic ovary syndrome. American Journal of Reproductive Immunology 80: e12839.

16. Popa-Nita, O., and P.H. Naccache. 2010. Crystal-induced neutrophil activation. Immunology and Cell Biology 88: 32–40. https://doi.org/10.1038/icb.2009.98.

17. D-I, Ren, C. Ji, X.-B. Wang, H. Wang, and B. Hu. 2017. Endogenous melatonin promotes rhythmic recruitment of neutrophils toward an injury in zebrafish. Scientific Reports 7: 1–10.

18. Agudelo, C.A., and C.M. Wise. 2000. Crystal-associated arthritis in the elderly. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 52: 3248–3256.
20. Matsubara, E., T. Bryant-Thomas, Quinto J. Pacheco, T.L. Henry, B. Poeggeler, D. Herbert, F. Cruz-Sanchez, Y.J. Chyan, M.A. Smith, and G. Perry. 2003. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer’s disease. *Journal of Neurochemistry* 85: 1101–1108.

21. Öztürk, G., K.G. Akbulut, Ş Güney, and D. Acuna-Castroviejo. 2012. Age-related changes in the rat brain mitochondrial antioxidative enzyme ratios: Modulation by melatonin. *Experimental Gerontology* 47: 706–711.

22. Coderre, T.J., and P.D. Wall. 1988. Ankle joint arthritic in rats provides a useful tool for the evaluation of analgesic and anti-arthritic agents. *Pharmacology Biochemistry and Behavior* 29: 461–466.

23. Czechowska, G., K. Celinski, A. Koroleczuk, G. Wojcicka, J. Dudka, A. Bojarska, and R.J. Reiter. 2015. Protective effects of melatonin against thiocacetamide-induced liver fibrosis in rats. *Journal of Physiology and Pharmacology* 66: 567–579.

24. Ahmed, A.S., J. Li, M. Ahmed, L. Hua, T. Yakovleva, M.H. Ossipov, G. Bakalkin, and A. Stark. 2010. Attenuation of pain and inflammation in adjuvant-induced arthritis by the post-some inhibitor MG132. *Arthritis & Rheumatism* 62: 2160–2169.

25. Ohkawa, H., N. Ohishi, and K. Yagi. 1979. Assay for lipid peroxides in animals tissues by thiobarbituric acid reaction. *Analytical Biochemistry* 95: 351–358.

26. Ellman, G.L. 1959. Tissue sulfhydryl groups. *Archives of Biochemistry and Biophysics* 82: 70–77.

27. Sun, Y., L.W. Oberley, and Y. Li. 1988. A simple method for clinical assay of superoxide dismutase. *Clinical Chemistry* 34: 497–500.

28. Burnie, J., A. Coke, and R. Matthews. 1992. Restriction endonuclease analysis of Aspergillus fumigatus DNA. *Journal of Clinical Pathology* 45: 324–327.

29. Lowry, O.H., N.J. Rosebrough, A.L. Farr, and R.J. Randall. 1951. Protein measurement with the Folin phenol reagent. *Journal of Biological Chemistry* 193: 265–275.

30. Erel, O. 2005. A new automated colorimetric method for measuring total oxidant status. *Clinical Biochemistry* 38: 1103–1111.

31. Bonnefont-Rousselot, D., and F. Collin. 2010. Melatonin: Action as antioxidant and potential applications in human disease and aging. *Toxicology* 278: 55–67.

32. Esteban-Zúbero, E., L. López-Pingarrón, M.A. Alatorre-Jiménez, P. Ochoa-Moneo, C. Buisac-Ramón, M. Rivas-Jiménez, S. Castaneda-Lombarte, D.-X. Tan, and J.J. García. 2017. Melatonin’s role as a co-adjuvant treatment in colonic diseases: A review. *Life Sciences* 170: 72–81.

33. Reiter, R.J., D.X. Tan, S. Rosales-Corral, A. Galano, X.J. Zhou, and B. Xu. 2018. Mitochondria: Central organelles for melatonin’s antioxidant and anti-aging actions. *Molecules* 23: 509.

34. Jahuanan-Esfahan, R., S. Mehrzadi, R.J. Reiter, K. Seidi, M. Majidinia, H.B. Baghi, N. Khatami, B. Yousefi, and A. Sadeghpour. 2018. Melatonin in regulation of inflammatory pathways in rheumatoid arthritis and osteoarthritis: Involvement of circadian clock genes. *British Journal of Pharmacology* 175: 3230–3238.

35. Cardinali, D.P., A.P. García, P. Cano, and A.I. Esquifino. 2004. Melatonin role in experimental arthritis. *Current Drug Targets-Endocurie & Metabolic Disorders* 4: 1–10.

36. Chen, H., S. Zheng, Y. Wang, H. Zhu, Q. Liu, Y. Xue, J. Qiu, H. Zou, and X. Zhu. 2016. The effect of resveratrol on the recurrent attacks of gouty arthritis. *Clinical Rheumatology* 35: 1189–1195.

37. Cao, Y. 2021. Icariin alleviates MSU-induced rat GA models through NF-κB/NALP3 pathway. *Cell Biochemistry and Function* 39: 357–366.

38. Dhansakar C., S. Kalaiselvan, and M. Rasool. 2015. Morin, a bioflavonoid suppresses monosodium urate crystal-induced inflammatory immune response in RAW 264.7 macrophages through the inhibition of inflammatory mediators, intracellular ROS levels and NF-κB activation. *PLoS One* 10:e0143093.

39. Shi, L., Z. Yuan, J. Liu, R. Cai, M. Hasnat, H. Yu, J. Feng, Z. Wang, Q. Zhao, and Wu M. 2021. Modified Simiaowan prevents articular cartilage injury in experimental gouty arthritis by negative regulation of STAT3 pathway. *Journal of Ethnopharmacology* 270:113285.

40. Bernardes, A.C.F.P.F., R.C. Matosinhos, M.C.D.P.M. Araújo, C.H. Barros, R.D.D.O.A. Soares, D.C. Costa, D. Sachs, and Saúde-Guimarães DA. 2021. Sesquiterpene lactones from Lychnophora species: Antinociceptive, anti-inflammatory, and antioxidant pathways to treat acute gout. *Journal of Ethnopharmacology* 269:113738.

41. Xiao, W.Z., L. Zhao, L. Cao, X.X. Zhu, and H.J. Zou. 2021. Melatonin Alleviates Acute Gouty Inflammation In Vivo and In Vitro. *Current Medical Science* 1–7.

42. Han, J., Y. Xie, F. Sui, C. Liu, X. Du, C. Liu, X. Feng, and D. Jiang. 2016. Zisheng Shenqi decoction ameliorates monosodium urate crystal-induced gouty arthritis in rats through anti-inflammatory and anti-oxidative effects. *Molecular Medicine Reports* 14: 2589–2597.

43. Cronstein, B.N., and R. Tarketaub. 2006. The inflammatory process of gout and its treatment. *Arthritis Research & Therapy* 8: 1–7.

44. Han, J., G. Shi, Li W., Wang S., Bai J., Sun X., Xie Y., Sui F., Chen, and D. Jiang. 2021. Zisheng Shenqi Decoction Ameliorates Monosodium Urate-Mediated Gouty Arthritis in Rats via Promotion of Autophagy through the AMPK/mTOR Signaling Pathway. *Evidence-Based Complementary and Alternative Medicine.*

45. Wang, G., T. Zuo, R. Li, and Z. Zuo. 2021. Effect of rebamipide on the acute gouty arthritis in rats induced by monosodium urate crystals. *Clinical Biochemistry* 152: 103460.

46. Ma, T.H., T. Sheng, C.M. Tian, M.Y. Xing, L.J. Yan, and D.Z. Xia. 2019. Effect of ethanolic extract of Polygonum cuspidatum on acute gouty arthritis in mice through NLRP3/ASC/caspase-1 axis. *Zhongguo Zhong yao za zhi= Zhongguo zhongyao zazhi= China Journal of Chinese Materia Medica* 44:546–552.

47. Galano, A., and R.J. Reiter. 2018. Melatonin and its metabolites vs oxidative stress: From individual actions to collective protection. *Journal of Pineal Research* 65:e12514.

48. Rizzo, A.M., P. Berselli, S. Zava, G. Montorfano, M. Negroni, P. Corsetto, and B. Berra. 2010. Endogenous antioxidants and radical scavengers, 52–67. *Bio-Farms for Nutraceuticals: Springer.*

49. Zoghebi, K.A., E. Bousoik, K. Parang, and K.A. Elsaid. 2020. Ossipov, G. Bakalkin, and A. Stark. 2010. Attenuation of pain and inflammation in adjuvant-induced arthritis by the post-some inhibitor MG132. *Clinical Biochemistry* 170: 72–81.

50. Reiter, R.J., D.X. Tan, S. Rosales-Corral, A. Galano, X.J. Zhou, and B. Xu. 2018. Mitochondria: Central organelles for melatonin’s antioxidant and anti-aging actions. *Molecules* 23: 509.

51. Serel, T.A., F. Özguner, and S. Soyupek. 2004. Prevention of shock wave-induced renal oxidative stress by melatonin: An experimental study. *Urological Research* 32: 69–71.

52. Zhao, P., K.L. Chen, G.L. Zhang, G.R. Deng, and J. Li. 2017. Pharmacological basis for use of Selaginella moellendorffii in gouty arthritis: anti-inflammatory, anti-oxidative effects. * Evidence-based complementary and alternative medicine.*

53. Serel, T.A., F. Özguner, and S. Soyupek. 2004. Prevention of shock wave-induced renal oxidative stress by melatonin: An experimental study. *Urological Research* 32: 69–71.

54. Jiang, X.-L., M. Li, J.-G. Zhou, Q.-B. Yang, L.-J. Du, and J. Du. 2011. Plasma paraoxonase-1, oxidized low-density lipoprotein and lipid peroxidation levels in gout patients. *Cell Biochemistry and Biophysics* 61: 461–466.
53. Kumar, M., E.R. Kasala, L.N. Bodduluru, V. Dahiya, and M. Lahkar. 2016. Baicalein protects isoproterenol induced myocardial ischemic injury in male Wistar rats by mitigating oxidative stress and inflammation. *Inflammation Research* 65: 613–622.

54. Acharya, C., A. Sharma, and N. Kantharia. 2015. Involvement of oxidative stress in patients of gout and antioxidant effect of allopurinol. *International Journal of Medical Science and Public Health* 4: 168–172.

55. Rossaneis, A.C., D.T. Longhi-Balbinot, M.M. Bertozzi, V. Fattori, C.Z. Segato-Vendrameto, S. Badaro-Garcia, T.H. Zaninelli, L. Staurengo-Ferrari, S.M. Borghi, and T.T. Carvalho. 2019. [Ru (bpy) 2 (NO) SO3] (PF6), a Nitric Oxide Donating Ruthenium Complex, Reduces Gout Arthritis in Mice. *Frontiers in Pharmacology* 10: 229.

56. Ruiz-Miyazawa, K.W., L. Staurengo-Ferrari, F.A. Pinho-Ribeiro, V. Fattori, T.H. Zaninelli, S. Badaro-Garcia, S.M. Borghi, K.C. Andrade, J.T. Clemente-Napimoga, and J.C. Alves-Filho. 2018. 15d-PGJ2-loaded nanocapsules ameliorate experimental gout arthritis by reducing pain and inflammation in a PPAR-gamma-sensitive manner in mice. *Scientific Reports* 8: 1–13.

57. Scher, J.U., and M.H. Pillinger. 2005. 15d-PGJ2: The anti-inflammatory prostaglandin? *Clinical Immunology* 114: 100–109.

58. Mahmoud, A.M., W.G. Hozayen, and S.M. Ramadan. 2017. Berberine ameliorates methotrexate-induced liver injury by activating Nrf2/HO-1 pathway and PPARγ, and suppressing oxidative stress and apoptosis in rats. *Biomedicine & Pharmacotherapy* 94: 280–291.

59. Voshaar, M.A.O., T. Bardin, and M.A. van de Laar. 2015. The human and economic burden of difficult-to-treat gouty arthritis. *Joint Bone Spine* 82: eS2–eS8.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.